Lawrence Steinman

Publication Details

  • Short peptide-based tolerogens without self-antigenic or pathogenic activity reverse autoimmune disease JOURNAL OF IMMUNOLOGY Karin, N., Binah, O., Grabie, N., Mitchell, D. J., Felzen, B., Solomon, M. D., Conlon, P., Gaur, A., Ling, N., Steinman, L. 1998; 160 (10): 5188-5194


    An immunodominant epitope of myelin basic protein (MBP), VHFFKNIVTPRTP (p87-99), is a major target of T cells in brain lesions of multiple sclerosis (MS), and this peptide can trigger experimental autoimmune encephalomyelitis (EAE). We designed truncated peptides based on this pathogenic 13-mer that are not antigenic. These short peptides reduced production of IFN-gamma and TNF-alpha in vivo. Moreover, paraplegic rats given the 7-mer FKNIVTP in soluble form showed total reversal of paralysis in 24 h. Truncated peptides that are too small to stimulate antigenic responses to pathogenic regions of myelin basic protein are nevertheless effective tolerogens and are able to anergize autoreactive T cells. Short peptide-based tolerogens, devoid of immunogenic and pathogenic potential, may be attractive for therapy of autoimmune diseases.

    View details for Web of Science ID 000073500000064

    View details for PubMedID 9590272

Stanford Medicine Resources:

Footer Links: